UBS Group’s iShares Biotechnology ETF IBB Stock Holding History

UBS Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50,000	Closed	-$6.33M	–	10573
2025 Q2	$6.33M	Buy	+50,000	New	+$6.14M	﹤0.01%	3625
2025 Q1	–	Sell	-123,800	Closed	-$16.4M	–	10449
2024 Q4	$16.4M	Buy	123,800 +93,800	+313%	+$13.2M	﹤0.01%	2546
2024 Q3	$4.37M	Hold	30,000	–	–	﹤0.01%	3213
2024 Q2	$4.12M	Hold	30,000	–	–	﹤0.01%	3054
2024 Q1	$4.12M	Sell	30,000 -58,000	-66%	-$7.92M	﹤0.01%	3180
2023 Q4	$12M	Sell	88,000 -110,100	-56%	-$13.4M	﹤0.01%	1951
2023 Q3	$24.2M	Buy	198,100 +116,500	+143%	+$14.8M	0.01%	1336
2023 Q2	$10.4M	Buy	81,600 +59,600	+271%	+$7.74M	﹤0.01%	1937
2023 Q1	$2.84M	Sell	22,000 -78,000	-78%	-$10.2M	﹤0.01%	3051
2022 Q4	$13.1M	Hold	100,000	–	–	﹤0.01%	1712
2022 Q3	$11.7M	Hold	100,000	–	–	0.01%	1660
2022 Q2	$11.8M	Buy	+100,000	New	+$11.9M	﹤0.01%	1690
2022 Q1	–	Sell	-100,000	Closed	-$15.3M	–	10523
2021 Q4	$15.3M	Hold	100,000	–	–	﹤0.01%	1780
2021 Q3	$16.2M	Hold	100,000	–	–	0.01%	1665
2021 Q2	$16.4M	Hold	100,000	–	–	0.01%	1648
2021 Q1	$15.1M	Sell	100,000 -6,500	-6%	-$1.03M	0.01%	1627
2020 Q4	$16.1M	Sell	106,500 -96,000	-47%	-$13.7M	0.01%	1496
2020 Q3	$27.4M	Buy	202,500 +100,000	+98%	+$13.6M	0.01%	975
2020 Q2	$14M	Sell	102,500 -100	-0.1%	-$12.7K	0.01%	1283
2020 Q1	$11.1M	Sell	102,600 -248,400	-71%	-$28.6M	0.01%	1333
2019 Q4	$42.3M	Sell	351,000 -134,000	-28%	-$15M	0.01%	865
2019 Q3	$48.3M	Buy	485,000 +14,800	+3%	+$1.55M	0.02%	711
2019 Q2	$51.3M	Buy	470,200 +212,500	+82%	+$22.6M	0.02%	657
2019 Q1	$28.8M	Sell	257,700 -203,500	-44%	-$22.3M	0.01%	924
2018 Q4	$44.5M	Buy	461,200 +80,000	+21%	+$8.49M	0.02%	641
2018 Q3	$46.5M	Buy	381,200 +84,200	+28%	+$9.92M	0.02%	714
2018 Q2	$32.6M	Sell	297,000 -60,100	-17%	-$6.43M	0.01%	891
2018 Q1	$38.1M	Sell	357,100 -424,500	-54%	-$47.1M	0.02%	768
2017 Q4	$83.5M	Buy	781,600 +270,700	+53%	+$28.9M	0.03%	466
2017 Q3	$56.8M	Buy	510,900 +50,700	+11%	+$5.42M	0.03%	545
2017 Q2	$47.6M	Sell	460,200 -795,300	-63%	-$78.3M	0.02%	582
2017 Q1	$123M	Buy	1,255,500 +975,000	+348%	+$93.3M	0.07%	282
2016 Q4	$24.8M	Sell	280,500 -124,500	-31%	-$11.3M	0.01%	902
2016 Q3	$39.1M	Sell	405,000 -90,000	-18%	-$8.56M	0.02%	619
2016 Q2	$42.5M	Buy	495,000 +174,000	+54%	+$15.6M	0.03%	561
2016 Q1	$27.9M	Buy	321,000 +215,700	+205%	+$19.3M	0.02%	702
2015 Q4	$11.9M	Sell	105,300 -303,000	-74%	-$32.9M	0.01%	1285
2015 Q3	$41.3M	Buy	408,300 +408,000	+136,000%	+$48.9M	0.03%	539
2015 Q2	$37K	Sell	300 -111,300	-100%	-$13.3M	﹤0.01%	6279
2015 Q1	$12.8M	Sell	111,600 -63,300	-36%	-$6.98M	0.01%	1277
2014 Q4	$17.7M	Buy	+174,900	New	+$17M	0.01%	1079

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group's IBB Position: Q1 2026 in Review

UBS Group reduced its iShares Biotechnology ETF (IBB) stake by 11% in Q1 2026, selling an estimated $16.9M and leaving 814,290 shares worth $137M. The position accounts for 0.02% of the portfolio, ranked #818.

UBS Group first reported a position in IBB in Q4 2014 and has held it in 46 quarters since. The position peaked at $629M in Q2 2019. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

UBS Group held 814,290 shares of iShares Biotechnology ETF worth $137M as of Q1 2026.
UBS Group sold 98,745 iShares Biotechnology ETF shares in Q1 2026, an estimated $16.9M.
iShares Biotechnology ETF made up 0.02% of UBS Group's portfolio in Q1 2026, its #818 holding.
UBS Group first reported a position in iShares Biotechnology ETF in Q4 2014 and has held it in 46 quarters since.
UBS Group's iShares Biotechnology ETF position peaked at $629M in Q2 2019.
917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.